<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-8-277</article-id><article-id pub-id-type="pmid">18826606</article-id><article-id pub-id-type="doi">10.1186/1471-2407-8-277</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The effects of timing of fine needle aspiration biopsies on gene expression profiles in breast cancers</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Wong</surname><given-names>Vietty</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>viettyw@uhnresearch.ca</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Wang</surname><given-names>Dong-Yu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dwang@uhnres.utoronto.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Warren</surname><given-names>Keisha</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kwarren@uhnres.utoronto.ca</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Kulkarni</surname><given-names>Supriya</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>supriya.kulkarni@uhn.on.ca</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Boerner</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>scott.boerner@uhn.on.ca</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Done</surname><given-names>Susan Jane</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>sdone@uhnres.utoronto.ca</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Leong</surname><given-names>Wey Liang</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I6">6</xref><xref ref-type="aff" rid="I7">7</xref><email>wey.leong@uhn.on.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, Toronto, Canada</aff><aff id="I2"><label>2</label>Department of Radiology, Princess Margaret Hospital, University Health Network, Toronto, Canada</aff><aff id="I3"><label>3</label>Department of Pathology, Princess Margaret Hospital, University Health Network, Toronto, Canada</aff><aff id="I4"><label>4</label>Departments of Laboratory Medicine and Pathobiology Toronto, Canada</aff><aff id="I5"><label>5</label>Medical Biophysics, University of Toronto, Toronto, Canada</aff><aff id="I6"><label>6</label>Department of General Surgery, University Health Network, University of Toronto, Toronto, Canada</aff><aff id="I7"><label>7</label>Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>30</day><month>9</month><year>2008</year></pub-date><volume>8</volume><fpage>277</fpage><lpage>277</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/277"/><history><date date-type="received"><day>28</day><month>2</month><year>2008</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Wong et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Wong et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Wong Vietty viettyw@uhnresearch.ca </dc:author><dc:title> The effects of timing of fine needle aspiration biopsies on gene expression profiles in breast cancers </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Cancer 8(1): 277-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2008)8:1&#x0003c;277&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>DNA microarray analysis has great potential to become an important clinical tool to individualize prognostication and treatment for breast cancer patients. However, with any emerging technology, there are many variables one must consider before bringing the technology to the bedside. There are already concerted efforts to standardize protocols and to improve reproducibility of DNA microarray. Our study examines one variable that is often overlooked, the timing of tissue acquisition, which may have a significant impact on the outcomes of DNA microarray analyses especially in studies that compare microarray data based on biospecimens taken <italic>in vivo </italic>and <italic>ex vivo</italic>.</p></sec><sec sec-type="methods"><title>Methods</title><p>From 16 patients, we obtained paired fine needle aspiration biopsies (FNABs) of breast cancers taken before (PRE) and after (POST) their surgeries and compared the microarray data to determine the genes that were differentially expressed between the FNABs taken at the two time points. qRT-PCR was used to validate our findings. To examine effects of longer exposure to hypoxia on gene expression, we also compared the gene expression profiles of 10 breast cancers from clinical tissue bank.</p></sec><sec><title>Results</title><p>Using hierarchical clustering analysis, 12 genes were found to be differentially expressed between the FNABs taken before and after surgical removal. Remarkably, most of the genes were linked to FOS in an early hypoxia pathway. The gene expression of FOS also increased with longer exposure to hypoxia.</p></sec><sec><title>Conclusion</title><p>Our study demonstrated that the timing of fine needle aspiration biopsies can be a confounding factor in microarray data analyses in breast cancer. We have shown that FOS-related genes, which have been implicated in early hypoxia as well as the development of breast cancers, were differentially expressed before and after surgery. Therefore, it is important that future studies take timing of tissue acquisition into account.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>DNA microarray analysis is an evolving high-throughput molecular technology that enables scientists to survey thousands of genes simultaneously. The resulting gene profiles (GPs) have been employed for the investigation of complex multi-factorial diseases such as breast cancer. In breast cancer, GPs have been shown to correlate with many clinically relevant clinico-pathological parameters, to prognosticate survival and predict treatment responses to specific chemotherapeutic regimens [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Despite its potential in clinical applications, one of the main hurdles to be overcome is the reproducibility of DNA microarray data due to several variables that may influence the results. These variables include different protocols used in tissue handling, RNA extractions and amplifications, microarray platforms and statistical analyses. Efforts are underway to standardize and validate the procedure. One such important initiative is the Microarray Quality Control (MAQC) project launched by the US Food and Drug Administration (FDA) [<xref ref-type="bibr" rid="B10">10</xref>]. It compared microarray data using identical RNA samples on three different DNA microarray platforms from independent laboratories. They demonstrated that in well designed studies under strict conditions, the microarray technology is highly reproducible. The FDA has recently approved several microarray platforms for clinical use.</p><p>In this study, we examined the hypothesis that timing of tissue acquisition, either taken pre- or post-operatively (<italic>in vivo </italic>or <italic>ex vivo</italic>, respectively), is one of the important variables that may influence DNA microarray results. Many studies have failed to report or control for this variable. It is particularly important when comparing studies designed to evaluate gene profiles of <italic>in vivo </italic>specimens such as those obtained in the neo-adjuvant setting, to more traditional studies that evaluate gene profiles in <italic>ex vivo </italic>specimens from surgery or tissue banks.</p><p>Fine needle aspiration biopsies (FNABs) have been used successfully to obtain cancer cells for DNA microarray studies [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. As compared with core biopsy or surgically resected specimens, FNAB specimens appear to enrich for epithelial cells with comparable yield in RNA [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Additional advantages of using FNABs include the ability to obtain specimens for microarray analyses without significant compromise of standard histological assessments, and the ability to assess cytology of these FNAB specimens.</p><p>In this study, we compared GPs from FNABs taken pre-operatively and post-operatively in 16 patients to determine the effects of timing on the microarray data. To identify genes that may potentially confound with gene signatures in DNA microarray data.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and fine needle aspirate biopsies (FNAB)</title><p>Sixteen patients with known palpable invasive breast cancer planned to have surgery for the primary tumors and nodal assessment, were recruited into the study at Princess Margaret Hospital (Toronto, On). This study was approved by our institutional research ethics committee, University Health Network Research Ethics Board, and all patients gave written informed consent. In each of the 16 patients, the first FNAB was taken before surgery (PRE) and the second FNAB was taken immediately after the surgical removal of the tumor in the operating room (POST). FNABs were obtained using a 25-gauge needle on a 10-cc syringe, with the needle passing the tumor 10 to 20 times. Two needle biopsies were utilized for each time point. An aliquot of the FNAB was placed into 15 ml of CytoLyt (Cytyc Corp; Marlborough, MA) for cytological analyses by the cytopathologist (SB). The remaining cells in the FNABs were placed into 500 &#x003bc;l of RNA extraction lysis buffer (Qiagen; Valencia, CA) and were immediately lysed by repeatedly passing the suspension through the FNAB needle and then quick frozen to -80&#x000b0;C and stored for later processing. Table <xref ref-type="table" rid="T1">1</xref> summarizes the clinico-pathological features of the 16 patients, FNAB cytology and RNA yields from each of the two time points.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Tumor clinico-pathological features, cytology, and RNA yields of the patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Patient No.</td><td align="center">Tumor Type</td><td align="center">Tumor Size<break/>(cm)</td><td align="center">Tumor Grade</td><td align="center">ER*</td><td align="center">PR*</td><td align="center">HER2*</td><td align="center">Positive Nodes</td><td align="center">PRE Total RNA<break/>(&#x003bc;g)</td><td align="center">PRE Tumor Cell<break/>(%)</td><td align="center">POST Total RNA<break/>(&#x003bc;g)</td><td align="center">POST Tumor Cell<break/>(%)</td></tr></thead><tbody><tr><td align="center">1</td><td align="center">IDC</td><td align="center">2.8/2.6</td><td align="center">2 &#x00026; 3</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">2&#x02013;26</td><td align="center">9.6</td><td align="center">&#x0003e;99</td><td align="center">15.4</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">2</td><td align="center">IDC</td><td align="center">1.9</td><td align="center">3</td><td align="center">+</td><td align="center">+</td><td align="center">-</td><td align="center">0/12</td><td align="center">0.8</td><td align="center">&#x0003e;99</td><td align="center">1.4</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">3</td><td align="center">IDC</td><td align="center">2</td><td align="center">3</td><td align="center">+</td><td align="center">+</td><td align="center">-</td><td align="center">1&#x02013;17</td><td align="center">0.4</td><td align="center">&#x0003e;99</td><td align="center">9.8</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">4</td><td align="center">IDC</td><td align="center">1.6</td><td align="center">3</td><td align="center">+</td><td align="center">+</td><td align="center">-</td><td align="center">1&#x02013;4</td><td align="center">1.9</td><td align="center">&#x0003e;99</td><td align="center">1.4</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">5</td><td align="center">IDC</td><td align="center">3</td><td align="center">2</td><td align="center">+</td><td align="center">-</td><td align="center">-</td><td align="center">0/16</td><td align="center">0.2</td><td align="center">&#x0003e;99</td><td align="center">1</td><td align="center">**</td></tr><tr><td align="center">6</td><td align="center">IDC</td><td align="center">15</td><td align="center">3</td><td align="center">+</td><td align="center">+</td><td align="center">-</td><td align="center">29/32</td><td align="center">0.5</td><td align="center">&#x0003e;99</td><td align="center">1.8</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">7</td><td align="center">IDC</td><td align="center">4.5</td><td align="center">3</td><td align="center">-</td><td align="center">-</td><td align="center">+</td><td align="center">0/11</td><td align="center">7.6</td><td align="center">&#x0003e;99</td><td align="center">30.4</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">8</td><td align="center">IDC</td><td align="center">1.6</td><td align="center">2</td><td align="center">+</td><td align="center">+</td><td align="center">-</td><td align="center">0/16</td><td align="center">1.4</td><td align="center">&#x0003e;99</td><td align="center">3.7</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">9</td><td align="center">IDC</td><td align="center">1.7</td><td align="center">3</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">1&#x02013;18</td><td align="center">2</td><td align="center">&#x0003e;99</td><td align="center">1.1</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">10</td><td align="center">IDC</td><td align="center">2.2/1.0</td><td align="center">3</td><td align="center">-</td><td align="center">-</td><td align="center">+</td><td align="center">2&#x02013;17</td><td align="center">7.5</td><td align="center">&#x0003e;99</td><td align="center">3.4</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">11</td><td align="center">IDC/lobular</td><td align="center">6.5</td><td align="center">2</td><td align="center">+</td><td align="center">+</td><td align="center">-</td><td align="center">8&#x02013;15</td><td align="center">1.5</td><td align="center">&#x0003e;99</td><td align="center">3.2</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">12</td><td align="center">IDC</td><td align="center">2.5</td><td align="center">3</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">8&#x02013;25</td><td align="center">1.3</td><td align="center">**</td><td align="center">12.4</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">13</td><td align="center">IDC</td><td align="center">4</td><td align="center">2</td><td align="center">+</td><td align="center">+</td><td align="center">-</td><td align="center">2&#x02013;20</td><td align="center">4.2</td><td align="center">&#x0003e;99</td><td align="center">8.5</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">14</td><td align="center">IDC</td><td align="center">6.5</td><td align="center">2</td><td align="center">-</td><td align="center">-</td><td align="center">+</td><td align="center">1&#x02013;12</td><td align="center">9.5</td><td align="center">&#x0003e;99</td><td align="center">3.2</td><td align="center">&#x0003e;99</td></tr><tr><td align="center">15</td><td align="center">IDC</td><td align="center">2.1</td><td align="center">2</td><td align="center">+</td><td align="center">+</td><td align="center">-</td><td align="center">0/3</td><td align="center">1.2</td><td align="center">&#x0003e;99</td><td align="center">9.6</td><td align="center">50</td></tr><tr><td align="center">16</td><td align="center">IDC</td><td align="center">3.4</td><td align="center">2</td><td align="center">+</td><td align="center">+</td><td align="center">-</td><td align="center">0/3</td><td align="center">1.9</td><td align="center">&#x0003e;99</td><td align="center">0.4</td><td align="center">&#x0003e;99</td></tr></tbody></table><table-wrap-foot><p>ER, estrogen receptor; PR, progesterone receptor; HER2, Her2/neu receptor status; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.*ER, PR, and HER2 status as reported on standard surgical pathology reports were determined by immunohistochemistry, or by fluorescent in situ hybridization (FISH) for HER2 according to our institutional standard of practice. ** Cytology from FNABs of patient 5 POST and 12 PRE could not be determined due to low cellularity in the cytologic fractions.</p></table-wrap-foot></table-wrap></sec><sec><title>Tissue bank specimens</title><p>For comparison purposes, we obtained 10 fresh frozen random invasive breast cancer specimens from our institutional tissue bank (University Health Network Biobank). The tissue bank specimens were annotated with clinico-pathology information and taken from patients with breast cancers larger than 2 cm who had surgery at our institution.</p></sec><sec><title>RNA extraction and amplification</title><p>Frozen FNAB lysates were thawed in a 37&#x000b0;C water bath for 15 min, and RNA was extracted using RNAeasy Micro kit (Qiagen). 15&#x02013;20 mg of tissue bank specimens were placed into 700 &#x003bc;L of RNA extraction lysis buffer (Qiagen) and then homogenized using a PRO 200 rotor stator homogenizer (PRO Scientific Inc; Oxford, CT). The RNA was extracted using RNAeasy Lipid mini kit (Qiagen). Qualitative analyses of the RNA samples were determined using the Agilent 2100 Bioanalyzer RNA 6000 LabChip kit (Agilent Technologies; Palo Alto, CA). In many cases the RNA yields from the FNABs were less than 2 &#x003bc;g (Table <xref ref-type="table" rid="T1">1</xref>), to standardize the RNA processing, we amplified all the RNA samples using the MessageAmp aRNA amplification kit, a T7 based linear amplification (Ambion; Austin, Tx) in one round. 100&#x02013;1000 ng of total RNA was used as a starting amount for amplification according to the manufacturer's instructions.</p></sec><sec><title>Microarray hybridization</title><p>The amplified RNA species from FNABs and an amplified Universal Human Reference RNA (Stratagene; La Jolla, CA) were directly labeled using cyanine 3 and cyanine 5 fluorescent dyes for microarray hybridization. Direct labeling of the sample on glass slide Microarrays was preformed according to the protocol given by the University Health Network Microarrays Centre (University Health Network, Toronto, On) [<xref ref-type="bibr" rid="B18">18</xref>]. Briefly, first-strand cDNA synthesis was performed with Superscript II (Invitrogen; Carlsbad, CA) in the presence of cyanine 3-dCTP or cyanine 5-dCTP (Amersham; Little Chalfont, UK) from 5 to 10 &#x003bc;g of RNA. The generated cDNA probes were then purified and denatured. The labeled targets were hybridized to UHN h19k cDNA microarrays (single spotted cDNA microarray chips comprising of 19,008 characterized and unknown human ESTs) manufactured at the University Health Network Microarray Centre. Scanning of the microarrays was achieved by using the Axon Scanner 4000A (Molecular Devices Corp.; Sunnyvale, CA) to obtain 16 bit TIFF image files.</p></sec><sec><title>Microarray and statistical analysis</title><p>GenePix 6.0 (Molecular Devices Corp.) was used to analyze the TIFF image files of the h19k cDNA microarrays for quantitation. A total of 64 microarray image files of pre (PRE) and post-operative (POST) samples with dye-swap replicates from the 16 patients were analyzed. The raw data in GenePix report (GPR) format were directly transferred into Acuity 4.0 (Molecular Devices Corp.) for analysis. After Lowess slide normalization of the GPR files, any uninformative microarray data were flagged and filtered. The dye-swap signal ratios were inverted before the data of the replicate were combined. Probes with minimal changes in expression level (Log2 ratio &#x0003e;= 1 or &#x0003c;= -1 in not more than 2 tumors) were removed, resulting in a list of 4,056 probes (National Center for Biotechnology Information Gene Expression Omnibus depository [<xref ref-type="bibr" rid="B19">19</xref>], accession number GSE12072). Then t-Test and hierarchal clustering analyses were used to select differentially expressed genes. Subsequent statistical analyses were carried out using SPSS 13.0 (SPSS, INC., Chicago, IL). Pearson Correlation was used to measure the expression level similarities between the replicated microarrays as well as between the microarray and real-time quantitative RT-PCR (qRT-PCR) examinations. PathwayAssist 3.0 (Stratagene) was used to determine the gene product interactions, based on a reference database (Ariadne Inc. Rockville, MD), updated in October 2007. Downloaded annotation files of UHN h19k cDNA microarray were updated by using UniGene Human Build 211 (GPL7025).</p></sec><sec><title>Real-time quantitative RT-PCR(qRT-PCR)</title><p>The expression levels of selected genes in the microarray data were validated by performing qRT-PCR on the amplified RNA samples that were used for the microarray hybridization. qRT-PCR was performed using Gene Amp 9700 sequence detector (Applied Biosystems, Foster City, CA). Pre-designed Taqman gene expression assays (Applied Biosystems) were used for each gene using primers away from the 3' end sequence of the transcript. For all qRT-PCR reactions, standard concentration of assays and Universal TaqManPCR Mastermix (Applied Biosystems) were used. The Sequence Detection Software (Applied Biosystems) was used to obtain the amplification plot to quantify gene expression values using the cycle threshold method. Human universal Reference RNA (Stratagene) was used as the calibrator sample, and the housekeeping gene GAPDH served for the standardization of the individual PCR reactions.</p></sec></sec><sec><title>Results</title><sec><title>Comparison of Pre and Post-operative microarray profiles</title><p>After data filtering (see Methods section), a list of 4,056 cDNA probes remained informative. We then preformed a t-test on the log2 ratio of each cDNA probe to identify genes discriminating PRE and POST samples from each patient by using a P-value &#x0003c; 0.05 detection level. Then a hierarchical clustering analysis was used to separate the relatively homogeneous clusters. As a result, 14 cDNA probes representing 12 unique genes and one expressed sequence tag of an unknown gene (Fig. <xref ref-type="fig" rid="F1">1A</xref>) were identified (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Two cDNA probes corresponding to FOS were found to be most significant in differentiating PRE and POST specimens (P = 0.002 and 0.006).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Differential gene expression pattern of breast cancers between FNABs taken pre-operatively (PRE) and post-operatively (POST)</bold>. (A) Hierarchical clustering pattern of expression of 14 cDNA probes between PRE and POST FNABs (p &#x0003c; 0.05, t-test). Rows represent cDNA probes and columns represent FNAB samples. "PRE" and "POST" correspond to pre and post-operative biopsies for the respective samples. The expression level is depicted according to the color scale (bottom) which represents the Log2 ratio changes of the samples relative to the human universal reference RNA (Stratagene). Grey squares indicate missing or filter-excluded data. (B) Validation of <italic>FOS </italic>gene expression in cDNA microarray using qRT-PCR. qRT-PCR data shown are averages of duplicate measurements. The columns correspond to FOS expression data in the microarray and qRT-PCR from PRE and POST specimens. The rows represent the corresponding specimens. Each cell in the matrix represents the expression level of Log2 ratio for microarray or Log ratio for qRT-PCR relative to the human universal reference RNA (Stratagene).</p></caption><graphic xlink:href="1471-2407-8-277-1"/></fig></sec><sec><title>Biological relationships of differentially expressed genes from Pre and Post-operative microarray profiles</title><p>The biological relationships of the 12 genes differentiating PRE and POST GPs were further investigated using PathwayAssist 3.0 software (Stratagene). We searched using the shortest paths between the genes to make up their biological interaction network. The software recognized 11 of the 12 genes. Nine out of the 11 genes formed a network and they were linked directly or indirectly to FOS (Fig. <xref ref-type="fig" rid="F2">2</xref>). qRT-PCR was used to validate the expression level of FOS in each of the FNAB specimens (Fig. <xref ref-type="fig" rid="F1">1B</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Pathway linkage analysis of the differentially expressed genes between PRE and POST FNABs</bold>. Nine genes (blue halo), out of 11 differentially expressed genes, including FOS were linked in the analysis (PathwayAssist 3.0) and formed a network. The layout of cellular location for the proteins is graphically presented.</p></caption><graphic xlink:href="1471-2407-8-277-2"/></fig></sec><sec><title>Trends in FOS expression with prolonged ischemia</title><p>FOS is known to be expressed in hypoxic conditions [<xref ref-type="bibr" rid="B20">20</xref>], and we hypothesized that what we observed in the higher expression of multiple members of the FOS network was related to the length of ischemic exposure prior to biopsy. To test this hypothesis, we compared the expression levels of FOS in 10 surgical specimens of invasive breast cancers that were left in an ischemic state for at least 30 minutes before freezing (Figure <xref ref-type="fig" rid="F3">3</xref>) to our FNAB specimens. The cDNA microarray analyses showed that FOS expression levels in the tissue samples were indeed higher than that in PRE and POST FNAB specimens (P = 0.000023, p = 0.000071) (Fig <xref ref-type="fig" rid="F3">3A</xref> and <xref ref-type="fig" rid="F3">3B</xref>) with a trend of higher FOS expression with longer ischemic time. Figure <xref ref-type="fig" rid="F3">3C</xref> showed the concordance between the microarray expression levels of the two FOS probes and the qRT-PCR data in tissue samples.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>FOS expression in PRE, POST and tissue specimens of breast cancers</bold>. (A) The expression levels of two FOS probes in microarray data of PRE and POST FNAB from 16 cases of invasive breast cancers, and tissue specimens from 10 invasive breast cancers. (B) FOS expression changes among the different specimens for array probe 1 (PRE vs. POST, P = 0.002 and PRE vs. tissue, P = 0.000023) and array probe 2 (PRE vs. POST, P = 0.006 and PRE vs. tissue, P = 0.000071). (C) Comparison of FOS expression levels between microarrays and qRT-PCR data for tissue specimens of breast cancers. The correlation coefficients between FOS expression level detected by qRT-PCR and two array data for tissue specimens are 0.86 (P = 0.0015) and 0.79 (P = 0.0063).</p></caption><graphic xlink:href="1471-2407-8-277-3"/></fig></sec></sec><sec><title>Discussion</title><p>DNA microarray is an evolving technology that has promise in diagnosing and prognosticating clinical outcomes of breast cancers [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. This has led to increased efforts to standardize this technology [<xref ref-type="bibr" rid="B10">10</xref>]. Implementing standards for microarray technology involves controlling all the potential confounding variables systematically, from sample collection to microarray data management, to ensure reliability of test results. Our study examined one such variable that has not been addressed in previous studies, which is the timing of tissue acquisition for DNA microarray analyses.</p><p>In our study, we elected to use FNAB for tissue acquisition. When compared to core biopsy, FNAB appeared to be less invasive for the participating patients, and the cell specimens collected were mostly malignant cells (99% table <xref ref-type="table" rid="T1">1</xref>). The latter finding is consistent with a study by Symmans <italic>et al</italic>. [<xref ref-type="bibr" rid="B11">11</xref>] in which they reported enrichment of epithelial cells in FNAB as compared with core biopsy specimens. The loose cells collected appeared to improve RNA extraction from small biopsy specimens as it facilitates cell lysis without the need for tissue homogenization and with minimal contamination of other cellular components. Although the RNA yield is variable (0.2 to 30.4 ug, table <xref ref-type="table" rid="T1">1</xref>), overall, sufficient quantity and quality of RNA can be obtained for the purpose of molecular profiling when amplified. Several studies have assessed the fidelity of T7 based linear RNA amplifications and have shown that linear amplification with as little as 100 ng-1000 ng is highly representative [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. Due to variable RNA yields from FNABs, the qRT-PCR component of this study was performed on amplified RNA which may introduce 3' bias as a result of the amplification process. However, we did not observe significant 3' bias as we were able to correlate our microarray data even though the qRT-PCR primers were selected from sequences away from the 3' end of the transcripts. A number of gene expression profiling studies have also been able to validate their data using amplified RNA in qRT-PCR [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B29">29</xref>].</p><p>Gene profiles generated from the FNABs taken before and after surgery in general were reproducible except for the 12 genes related to FOS. Since FOS has previously been associated with ischemic conditions [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>], we hypothesized that this observation was due to the duration of exposure to hypoxia. We then tested the hypothesis by demonstrating a much higher FOS expression level, using DNA microarray and qRT-PCR, in fresh frozen tissue specimens that were exposed to a longer ischemic time (figure <xref ref-type="fig" rid="F3">3A, B</xref> and <xref ref-type="fig" rid="F3">3C</xref>). Our pre-operative tumor FNABs were performed on tumors that were still <italic>in vivo </italic>and the specimens were immediately placed in lysis buffer and snap frozen after the biopsy. The post-operative FNABs were obtained similarly but on <italic>ex vivo </italic>tumors after surgical excision in the operating room. In the case of tissue bank specimens, fresh surgical specimens were delivered to the pathology laboratory before freezing and therefore consistently experienced hypoxia much longer than the FNAB specimens. M&#x000fc;ller et al [<xref ref-type="bibr" rid="B20">20</xref>] reported that hypoxia can induce FOS expression as early as 15 minutes exposure to hypoxia but plateaus at about 30 minutes. This was consistent with our findings which demonstrated a higher level of FOS expression with longer ischemic time (Fig. <xref ref-type="fig" rid="F3">3</xref>).</p><p>Hypoxia can induce two classes of hypoxia-related genes: immediate early genes (induced within minutes) and delayed response genes (arising slowly over hours) [<xref ref-type="bibr" rid="B32">32</xref>]. FOS is an example of an immediate early gene, it complexes with JUN to form the activator protein-1 transcription factor complex (AP-1) which regulates gene expression in response to hypoxia, and it has been known to be associated with regulation of cell cycle activities such as cell proliferation, differentiation, transformation, and apoptotic cell death [<xref ref-type="bibr" rid="B30">30</xref>]. In classic hypoxia pathways activated through Hypoxia-Inducible Factor-1&#x003b1; (HIF1&#x003b1;), the response to hypoxia is delayed [<xref ref-type="bibr" rid="B32">32</xref>], these genes include vascular endothelial growth factor (VEGF) [<xref ref-type="bibr" rid="B33">33</xref>], erythrpoietin (EPO) [<xref ref-type="bibr" rid="B34">34</xref>], neuronal nitric oxide synthase (NOS) [<xref ref-type="bibr" rid="B35">35</xref>], endothelin 1 (EDN1) [<xref ref-type="bibr" rid="B36">36</xref>], lactate dehydrogenase A (LDHA) [<xref ref-type="bibr" rid="B37">37</xref>] glycolytic enzymes and glucose transporters such as glycolytic enzymes aldolase A(ALDA) and phosphoglycerate kinase 1 (PGK1) [<xref ref-type="bibr" rid="B38">38</xref>], Many of these hypoxia-related pathways have been implicated in adverse cancer biology and may be linked to chronic hypoxia and tumor necrosis [<xref ref-type="bibr" rid="B39">39</xref>].</p><p>From the 4,056 informative genes in our microarray data, we were not able to detect changes in gene expressions related to other hypoxic pathways before and after the surgery. Out of the twelve differentially expressed genes, only FOS had potential interactions with HIF pathway. FOS interacts with HIF1&#x003b1; via AP-1 complex [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. It is possible that in surgical specimens, the expressions of immediate early genes induced by hypoxia, including FOS, were elevated minutes after removal of the tumors. However, expressions of delayed response genes, such as those activated by HIF1&#x003b1;, were not significantly altered because they required a longer time to elicit any significant change. This would be consistent with our findings of elevated gene expressions in FOS-related hypoxia pathway but not in other hypoxic pathways mediated through HIF1&#x003b1;. However, given the limitations of our study, we are not able to rule out all the changes in other hypoxic pathways. After data filtering (see Methods section), some of the critical genes in these pathways, including HIF1&#x003b1; and VEGF, were not represented in our microarray data. Further study is needed to draw concrete conclusion on the other hypoxic pathways from our observations.</p><p>In addition to the effects of hypoxia, there was a possibility that the physiological responses to general anesthesia or the stress of the surgery could have caused the observed changes in tumor gene expression, if this was the case, the mechanism is currently unknown and it would appear to be mediated through FOS-related pathway.</p><p>Interestingly, FOS has been associated with breast cancer in a number of studies [<xref ref-type="bibr" rid="B41">41</xref>-<xref ref-type="bibr" rid="B44">44</xref>]. FOS is involved in the expression of genes associated with malignant progression such as metalloproteases that degrade the extracellular matrix that may facilitate invasion and metastasis [<xref ref-type="bibr" rid="B45">45</xref>-<xref ref-type="bibr" rid="B47">47</xref>]. Most previous microarray studies utilized banked tissue [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>] and hypoxia-related genes may influence the result of the clustering analyses by affecting the ranking of differentially expressed genes. For example, Sotiriou <italic>et al</italic>. [<xref ref-type="bibr" rid="B7">7</xref>] reported that FOS was one of the genes that separated basal 1 and 2 subtypes of breast cancers, although it is difficult to know if the group could draw a similar conclusion if they used <italic>in vivo </italic>specimens in their study instead. In contrast to the study by Sotiriou <italic>et al</italic>., Perou <italic>et al</italic>. [<xref ref-type="bibr" rid="B4">4</xref>] examined gene expression profiling on breast cancer tissue (unpublished data cited in [<xref ref-type="bibr" rid="B4">4</xref>]), they excluded a cluster of genes including FOS simply because the authors believed that these genes were induced by prolonged handling of samples following surgical resection. It is quite possible that early hypoxic genes such as FOS may affect the ranking of some genes in previously published gene signatures. Hence, timing of tissue acquisition must be considered when interpreting microarray data.</p></sec><sec><title>Conclusion</title><p>Our study demonstrated that expression of early hypoxic genes can be influenced by the timing of tissue acquisition. Notably FOS, which is one of the most differentially expressed genes between the two time points was implicated in both hypoxia [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B40">40</xref>] and other breast cancer gene signatures [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. Our study suggested that the timing of sample collection may confound microarray data analysis and therefore must be taken into consideration when designing future studies.</p></sec><sec><title>Abbreviations</title><p>FNAB: Fine Needle Aspiration Biopsy; PRE: Pre-operative; POST: Post-operative; GP: gene profiles; MAQC: Microarray Quality Control; FDA: US Food and Drug Administration; GPR; GenePix Report; ER: Estrogen Receptor; PR: Progesterone Receptor; Her2: Her2/neu receptor; IDC: Invasive Ductal Carcinoma; ILC: Invasive Lobular Carcinoma; RT: reverse-transcriptase; PCR: polymerase chain reaction; FOS and JUN are proto-oncogenes, AP-1: activator protein-1 transcription factor complex; HIF1&#x003b1;: hypoxia-inducible factor-1&#x003b1;; VEGF: vascular endothelial growth factor; EPO: erythrpoietin; NOS: neuronal nitric oxide synthase; EDN1: endothelin 1; LDHA: lactate dehydrogenase A; ALDA: glycolytic enzymes aldolase A; PGK1: phosphoglycerate kinase 1.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>VW participated in the design, experimentation, data collection, analysis, interpretation, research and wrote this manuscript. DYW participated in the study design, data analysis, and preparation of the table and figures for this manuscript. The interpretation of the cytology samples was performed by SB. SK performed the FNABs in the radiology suite. WLL conceived the study design and was involved in the data collection, interpretation and manuscript preparation as well as supervision of the overall project. KW provided technical expertise with the experiments. Critical revision of the manuscript was performed by VW, DYW, WLL, SJD. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/277/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>DNA Microarray data of genes differentiating PRE and POST FNAB samples. Genes differentially expressed between PRE and POST FNABs in DNA microarray analysis.</p></caption><media xlink:href="1471-2407-8-277-S1.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors would like to thank the University Health Network Microarrays Center and Dr. James Woodgett (Director of UHN-MAC) for providing assistance and the resources to generate the microarray data. We would also like to thank all the women who participated in the study, and Genome Canada (grant 777606577) for providing funding and financial support for this study.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertucci</surname><given-names>F</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Rougemont</surname><given-names>J</given-names></name><name><surname>Charafe-Jauffret</surname><given-names>E</given-names></name><name><surname>Cervera</surname><given-names>N</given-names></name><name><surname>Tarpin</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Xerri</surname><given-names>L</given-names></name><name><surname>Houlgatte</surname><given-names>R</given-names></name><name><surname>Jacquemier</surname><given-names>J</given-names></name><name><surname>Viens</surname><given-names>P</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name></person-group><article-title>Gene expression profiling identifies molecular subtypes of inflammatory breast cancer</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>2170</fpage><lpage>2178</lpage><pub-id pub-id-type="pmid">15781628</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name><name><surname>Dressman</surname><given-names>H</given-names></name><name><surname>Pittman</surname><given-names>J</given-names></name><name><surname>Tsou</surname><given-names>MH</given-names></name><name><surname>Horng</surname><given-names>CF</given-names></name><name><surname>Bild</surname><given-names>A</given-names></name><name><surname>Iversen</surname><given-names>ES</given-names></name><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>CM</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name><name><surname>Huang</surname><given-names>AT</given-names></name></person-group><article-title>Gene expression predictors of breast cancer outcomes</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1590</fpage><lpage>1596</lpage><pub-id pub-id-type="pmid">12747878</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>XJ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ryan</surname><given-names>PD</given-names></name><name><surname>Isakoff</surname><given-names>SJ</given-names></name><name><surname>Barmettler</surname><given-names>A</given-names></name><name><surname>Fuller</surname><given-names>A</given-names></name><name><surname>Muir</surname><given-names>B</given-names></name><name><surname>Mohapatra</surname><given-names>G</given-names></name><name><surname>Salunga</surname><given-names>R</given-names></name><name><surname>Tuggle</surname><given-names>JT</given-names></name><name><surname>Tran</surname><given-names>Y</given-names></name><name><surname>Tran</surname><given-names>D</given-names></name><name><surname>Tassin</surname><given-names>A</given-names></name><name><surname>Amon</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Enright</surname><given-names>E</given-names></name><name><surname>Stecker</surname><given-names>K</given-names></name><name><surname>Estepa-Sabal</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Younger</surname><given-names>J</given-names></name><name><surname>Balis</surname><given-names>U</given-names></name><name><surname>Michaelson</surname><given-names>J</given-names></name><name><surname>Bhan</surname><given-names>A</given-names></name><name><surname>Habin</surname><given-names>K</given-names></name><name><surname>Baer</surname><given-names>TM</given-names></name><name><surname>Brugge</surname><given-names>J</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Erlander</surname><given-names>MG</given-names></name><name><surname>Sgroi</surname><given-names>DC</given-names></name></person-group><article-title>A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen</article-title><source>Cancer Cell</source><year>2004</year><volume>5</volume><fpage>607</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">15193263</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>S&#x000f8;rlie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Rijn</surname><given-names>M van de</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Rees</surname><given-names>CA</given-names></name><name><surname>Pollack</surname><given-names>JR</given-names></name><name><surname>Ross</surname><given-names>DT</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><name><surname>Fluge</surname><given-names>O</given-names></name><name><surname>Pergamenschikov</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>SX</given-names></name><name><surname>L&#x000f8;nning</surname><given-names>PE</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>AL</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><article-title>Molecular portraits of human breast tumours</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">10963602</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;rlie</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Aas</surname><given-names>T</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Rijn</surname><given-names>M van de</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Thorsen</surname><given-names>T</given-names></name><name><surname>Quist</surname><given-names>H</given-names></name><name><surname>Matese</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Eystein L&#x000f8;nning</surname><given-names>P</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>AL</given-names></name></person-group><article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>10869</fpage><lpage>10874</lpage><pub-id pub-id-type="pmid">11553815</pub-id><pub-id pub-id-type="pmid">11553815</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Marron</surname><given-names>JS</given-names></name><name><surname>Nobel</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Pesich</surname><given-names>R</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Demeter</surname><given-names>J</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>L&#x000f8;nning</surname><given-names>PE</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>AL</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><article-title>Repeated observation of breast tumor subtypes in independent gene expression data sets</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>8418</fpage><lpage>8423</lpage><pub-id pub-id-type="pmid">12829800</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Neo</surname><given-names>SY</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Korn</surname><given-names>EL</given-names></name><name><surname>Long</surname><given-names>PM</given-names></name><name><surname>Jazaeri</surname><given-names>A</given-names></name><name><surname>Martiat</surname><given-names>P</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name></person-group><article-title>Breast cancer classification and prognosis based on gene expression profiles from a population-based study</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>10393</fpage><lpage>10398</lpage><pub-id pub-id-type="pmid">12917485</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van't Veer</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Vijver</surname><given-names>MJ van de</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Peterse</surname><given-names>HL</given-names></name><name><surname>Kooy</surname><given-names>K van der</given-names></name><name><surname>Marton</surname><given-names>MJ</given-names></name><name><surname>Witteveen</surname><given-names>AT</given-names></name><name><surname>Schreiber</surname><given-names>GJ</given-names></name><name><surname>Kerkhoven</surname><given-names>RM</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Linsley</surname><given-names>PS</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Friend</surname><given-names>SH</given-names></name></person-group><article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>530</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">11823860</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Langerod</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Nowels</surname><given-names>KW</given-names></name><name><surname>Nesland</surname><given-names>JM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Bukholm</surname><given-names>IK</given-names></name><name><surname>Karesen</surname><given-names>R</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name></person-group><article-title>Different gene expression patterns in invasive lobular and ductal carcinomas of the breast</article-title><source>Mol Biol Cell</source><year>2004</year><volume>15</volume><fpage>2523</fpage><lpage>2536</lpage><pub-id pub-id-type="pmid">15034139</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bammler</surname><given-names>T</given-names></name><name><surname>Beyer</surname><given-names>RP</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Boorman</surname><given-names>GA</given-names></name><name><surname>Boyles</surname><given-names>A</given-names></name><name><surname>Bradford</surname><given-names>BU</given-names></name><name><surname>Bumgarner</surname><given-names>RE</given-names></name><name><surname>Bushel</surname><given-names>PR</given-names></name><name><surname>Chaturvedi</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name><name><surname>Cunningham</surname><given-names>ML</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Dressman</surname><given-names>HK</given-names></name><name><surname>Fannin</surname><given-names>RD</given-names></name><name><surname>Farin</surname><given-names>FM</given-names></name><name><surname>Freedman</surname><given-names>JH</given-names></name><name><surname>Fry</surname><given-names>RC</given-names></name><name><surname>Harper</surname><given-names>A</given-names></name><name><surname>Humble</surname><given-names>MC</given-names></name><name><surname>Hurban</surname><given-names>P</given-names></name><name><surname>Kavanagh</surname><given-names>TJ</given-names></name><name><surname>Kaufmann</surname><given-names>WK</given-names></name><name><surname>Kerr</surname><given-names>KF</given-names></name><name><surname>Jing</surname><given-names>L</given-names></name><name><surname>Lapidus</surname><given-names>JA</given-names></name><name><surname>Lasarev</surname><given-names>MR</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Lobenhofer</surname><given-names>EK</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Malek</surname><given-names>RL</given-names></name><name><surname>Milton</surname><given-names>S</given-names></name><name><surname>Nagalla</surname><given-names>SR</given-names></name><name><surname>O'Malley</surname><given-names>JP</given-names></name><name><surname>Palmer</surname><given-names>VS</given-names></name><name><surname>Pattee</surname><given-names>P</given-names></name><name><surname>Paules</surname><given-names>RS</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Phillips</surname><given-names>K</given-names></name><name><surname>Qin</surname><given-names>LX</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Quigley</surname><given-names>SD</given-names></name><name><surname>Rodland</surname><given-names>M</given-names></name><name><surname>Rusyn</surname><given-names>I</given-names></name><name><surname>Samson</surname><given-names>LD</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>JL</given-names></name><name><surname>Sieber</surname><given-names>SO</given-names></name><name><surname>Slifer</surname><given-names>S</given-names></name><name><surname>Speer</surname><given-names>MC</given-names></name><name><surname>Spencer</surname><given-names>PS</given-names></name><name><surname>Sproles</surname><given-names>DI</given-names></name><name><surname>Swenberg</surname><given-names>JA</given-names></name><name><surname>Suk</surname><given-names>WA</given-names></name><name><surname>Sullivan</surname><given-names>RC</given-names></name><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Tennant</surname><given-names>RW</given-names></name><name><surname>Todd</surname><given-names>SA</given-names></name><name><surname>Tucker</surname><given-names>CJ</given-names></name><name><surname>Van Houten</surname><given-names>B</given-names></name><name><surname>Weis</surname><given-names>BK</given-names></name><name><surname>Xuan</surname><given-names>S</given-names></name><name><surname>Zarbl</surname><given-names>H</given-names></name><collab>Members of the Toxicogenomics Research Consortium</collab></person-group><article-title>Standardizing global gene expression analysis between laboratories and across platforms</article-title><source>Nat Methods</source><year>2005</year><volume>2</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">15846362</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>Ayers</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>EA</given-names></name><name><surname>Stec</surname><given-names>J</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Sneige</surname><given-names>N</given-names></name><name><surname>Buchholz</surname><given-names>TA</given-names></name><name><surname>Krishnamurthy</surname><given-names>S</given-names></name><name><surname>Ibrahim</surname><given-names>NK</given-names></name><name><surname>Buzdar</surname><given-names>AU</given-names></name><name><surname>Theriault</surname><given-names>RL</given-names></name><name><surname>Rosales</surname><given-names>MF</given-names></name><name><surname>Thomas</surname><given-names>ES</given-names></name><name><surname>Gwyn</surname><given-names>KM</given-names></name><name><surname>Green</surname><given-names>MC</given-names></name><name><surname>Syed</surname><given-names>AR</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name></person-group><article-title>Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core needle biopsy samples of breast carcinoma</article-title><source>Cancer</source><year>2003</year><volume>97</volume><fpage>2960</fpage><lpage>2971</lpage><pub-id pub-id-type="pmid">12784330</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>LM</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name></person-group><article-title>Quantitative examination of mechanophysical tumor cell enrichment in fine-needle aspiration specimens</article-title><source>Cancer</source><year>2002</year><volume>96</volume><fpage>275</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">12378594</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayers</surname><given-names>M</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>Stec</surname><given-names>J</given-names></name><name><surname>Damokosh</surname><given-names>AI</given-names></name><name><surname>Clark</surname><given-names>E</given-names></name><name><surname>Hess</surname><given-names>K</given-names></name><name><surname>Lecocke</surname><given-names>M</given-names></name><name><surname>Metivier</surname><given-names>J</given-names></name><name><surname>Booser</surname><given-names>D</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Royce</surname><given-names>M</given-names></name><name><surname>Arun</surname><given-names>B</given-names></name><name><surname>Whitman</surname><given-names>G</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Sneige</surname><given-names>N</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name></person-group><article-title>Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>2284</fpage><lpage>2293</lpage><pub-id pub-id-type="pmid">15136595</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Ormerod</surname><given-names>M</given-names></name><name><surname>Powles</surname><given-names>TJ</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Ashley</surname><given-names>SE</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name></person-group><article-title>Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma</article-title><source>Cancer</source><year>2000</year><volume>89</volume><fpage>2145</fpage><lpage>2152</lpage><pub-id pub-id-type="pmid">11147583</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pusztai</surname><given-names>L</given-names></name><name><surname>Ayers</surname><given-names>M</given-names></name><name><surname>Stec</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>E</given-names></name><name><surname>Hess</surname><given-names>K</given-names></name><name><surname>Stivers</surname><given-names>D</given-names></name><name><surname>Damokosh</surname><given-names>A</given-names></name><name><surname>Sneige</surname><given-names>N</given-names></name><name><surname>Buchholz</surname><given-names>TA</given-names></name><name><surname>Esteva</surname><given-names>FJ</given-names></name><name><surname>Arun</surname><given-names>B</given-names></name><name><surname>Cristofanilli</surname><given-names>M</given-names></name><name><surname>Booser</surname><given-names>D</given-names></name><name><surname>Rosales</surname><given-names>M</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name></person-group><article-title>Gene expression profiles obtained from fine-needle aspiration of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen negative and estrogen-positive tumors</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>2406</fpage><lpage>2415</lpage><pub-id pub-id-type="pmid">12855612</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Powles</surname><given-names>TJ</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Jazaeri</surname><given-names>AA</given-names></name><name><surname>Feldman</surname><given-names>AL</given-names></name><name><surname>Assersohn</surname><given-names>L</given-names></name><name><surname>Gadisetti</surname><given-names>C</given-names></name><name><surname>Libutti</surname><given-names>SK</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name></person-group><article-title>Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer</article-title><source>Breast Cancer Res</source><year>2002</year><volume>4</volume><fpage>R3</fpage><pub-id pub-id-type="pmid">12052255</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>Volm</surname><given-names>MD</given-names></name><name><surname>Shapiro</surname><given-names>RL</given-names></name><name><surname>Perkins</surname><given-names>AB</given-names></name><name><surname>Kim</surname><given-names>AY</given-names></name><name><surname>Demaria</surname><given-names>S</given-names></name><name><surname>Yee</surname><given-names>HT</given-names></name><name><surname>McMullen</surname><given-names>H</given-names></name><name><surname>Oratz</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>P</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name><name><surname>Muggia</surname><given-names>F</given-names></name></person-group><article-title>Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>4610</fpage><lpage>4617</lpage><pub-id pub-id-type="pmid">11156210</pub-id></citation></ref><ref id="B18"><citation citation-type="other"><article-title>University Health Network Microarrays Centre (University Health Network, Toronto, On) experimental protocols</article-title><ext-link ext-link-type="uri" xlink:href="http://www.microarrays.ca/support/proto.html"/></citation></ref><ref id="B19"><citation citation-type="other"><article-title>The National Center for Biotechnology Information Gene Expression Omnibus depository</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/geo/"/></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>JM</given-names></name><name><surname>Krauss</surname><given-names>B</given-names></name><name><surname>Kaltschmidt</surname><given-names>C</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name><name><surname>Rupec</surname><given-names>RA</given-names></name></person-group><article-title>Hypoxia Induces c-<italic>fos </italic>Transcription via a Mitogen-activated Protein Kinase-dependent Pathway</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>23435</fpage><lpage>23439</lpage><pub-id pub-id-type="pmid">9287359</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polacek</surname><given-names>DC</given-names></name><name><surname>Passerini</surname><given-names>AG</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Francesco</surname><given-names>NM</given-names></name><name><surname>Manduchi</surname><given-names>E</given-names></name><name><surname>Grant</surname><given-names>GR</given-names></name><name><surname>Powell</surname><given-names>S</given-names></name><name><surname>Bischof</surname><given-names>H</given-names></name><name><surname>Winkler</surname><given-names>H</given-names></name><name><surname>Stoeckert</surname><given-names>CJ</given-names><suffix>Jr</suffix></name><name><surname>Davies</surname><given-names>PF</given-names></name></person-group><article-title>Fidelity and enhanced sensitivity of differential transcription profiles following linear amplification of nanogram amounts of endothelial mRNA</article-title><source>Physiol Genomics</source><year>2003</year><volume>13</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">12700361</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name></person-group><article-title>Genomic-scale analysis of gene expression profiles in TNF-&#x003b1; treated human umbilical vein endothelial cells</article-title><source>Inflamm Res</source><year>2002</year><volume>51</volume><fpage>332</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">12146724</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baugh</surname><given-names>LR</given-names></name><name><surname>Hill</surname><given-names>AA</given-names></name><name><surname>Brown</surname><given-names>EL</given-names></name><name><surname>Hunter</surname><given-names>CP</given-names></name></person-group><article-title>Quantitative analysis of mRNA amplification by <italic>in vitro </italic>transcription</article-title><source>Nucleic Acids Res</source><year>2001</year><volume>29</volume><fpage>E29</fpage><pub-id pub-id-type="pmid">11222780</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tun</surname><given-names>HW</given-names></name><name><surname>Personett</surname><given-names>D</given-names></name><name><surname>Baskerville</surname><given-names>KA</given-names></name><name><surname>Menke</surname><given-names>DM</given-names></name><name><surname>Jaeckle</surname><given-names>KA</given-names></name><name><surname>Kreinest</surname><given-names>P</given-names></name><name><surname>Edenfield</surname><given-names>B</given-names></name><name><surname>Zubair</surname><given-names>AC</given-names></name><name><surname>O'Neill</surname><given-names>BP</given-names></name><name><surname>Lai</surname><given-names>WR</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>McKinney</surname><given-names>M</given-names></name></person-group><article-title>Pathway analysis of primary central nervous system lymphoma</article-title><source>Blood</source><year>2008</year><volume>111</volume><fpage>3200</fpage><lpage>3210</lpage><pub-id pub-id-type="pmid">18184868</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lathem</surname><given-names>WW</given-names></name><name><surname>Crosby</surname><given-names>SD</given-names></name><name><surname>Miller</surname><given-names>VL</given-names></name><name><surname>Goldman</surname><given-names>WE</given-names></name></person-group><article-title>Progression of primary pneumonic plague: A mouse model of infection, pathology, and bacterial transcriptional activity</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>17786</fpage><lpage>17791</lpage><pub-id pub-id-type="pmid">16306265</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>CS</given-names></name><name><surname>Bonin</surname><given-names>M</given-names></name><name><surname>Clare</surname><given-names>SE</given-names></name><name><surname>Nieselt</surname><given-names>K</given-names></name><name><surname>Sotlar</surname><given-names>K</given-names></name><name><surname>Walter</surname><given-names>M</given-names></name><name><surname>Fehm</surname><given-names>T</given-names></name><name><surname>Solomayer</surname><given-names>E</given-names></name><name><surname>Riess</surname><given-names>O</given-names></name><name><surname>Wallwiener</surname><given-names>D</given-names></name><name><surname>Kurek</surname><given-names>R</given-names></name><name><surname>Neubauer</surname><given-names>HJ</given-names></name></person-group><article-title>Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas <italic>In situ </italic>and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>5278</fpage><lpage>5286</lpage><pub-id pub-id-type="pmid">16707453</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahr&#x000e9;n</surname><given-names>D</given-names></name><name><surname>Tholander</surname><given-names>M</given-names></name><name><surname>Fekete</surname><given-names>C</given-names></name><name><surname>Rajashekar</surname><given-names>B</given-names></name><name><surname>Friman</surname><given-names>E</given-names></name><name><surname>Johansson</surname><given-names>T</given-names></name><name><surname>Tunlid</surname><given-names>A</given-names></name></person-group><article-title>Comparison of gene expression in trap cells and vegetative hyphae of the nematophagous fungus Monacrosporium haptotylum</article-title><source>Microbiology</source><year>2005</year><volume>151</volume><fpage>789</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">15758225</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sekiguchi</surname><given-names>N</given-names></name><name><surname>Kawauchi</surname><given-names>S</given-names></name><name><surname>Furuya</surname><given-names>T</given-names></name><name><surname>Inaba</surname><given-names>N</given-names></name><name><surname>Matsuda</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>S</given-names></name><name><surname>Ogasawara</surname><given-names>M</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Kameda</surname><given-names>H</given-names></name><name><surname>Amano</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name></person-group><article-title>Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab</article-title><source>Rheumatology (Oxford)</source><year>2008</year><volume>47</volume><fpage>780</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">18388148</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rise</surname><given-names>ML</given-names></name><name><surname>Jones</surname><given-names>SR</given-names></name><name><surname>Brown</surname><given-names>GD</given-names></name><name><surname>von Schalburg</surname><given-names>KR</given-names></name><name><surname>Davidson</surname><given-names>WS</given-names></name><name><surname>Koop</surname><given-names>BF</given-names></name></person-group><article-title>Microarray analyses identify molecular biomarkers of Atlantic salmon macrophage and hematopoietic kidney response to Piscirickettsia salmonis infection</article-title><source>Physiol Genomics</source><year>2004</year><volume>20</volume><fpage>21</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">15454580</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Premkumar</surname><given-names>DR</given-names></name><name><surname>Adhikary</surname><given-names>G</given-names></name><name><surname>Overholt</surname><given-names>JL</given-names></name><name><surname>Simonson</surname><given-names>MS</given-names></name><name><surname>Cherniack</surname><given-names>NS</given-names></name><name><surname>Prabhakar</surname><given-names>NR</given-names></name></person-group><article-title>Intracellular pathways linking hypoxia to activation of c-fos and AP-1</article-title><source>Adv Exp Med Biol</source><year>2000</year><volume>475</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">10849652</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spruessel</surname><given-names>A</given-names></name><name><surname>Steimann</surname><given-names>G</given-names></name><name><surname>Jung</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>SA</given-names></name><name><surname>Carr</surname><given-names>T</given-names></name><name><surname>Fentz</surname><given-names>AK</given-names></name><name><surname>Spangenberg</surname><given-names>J</given-names></name><name><surname>Zornig</surname><given-names>C</given-names></name><name><surname>Juhl</surname><given-names>HH</given-names></name><name><surname>David</surname><given-names>KA</given-names></name></person-group><article-title>Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision</article-title><source>Biotechniques</source><year>2004</year><volume>36</volume><fpage>1030</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">15211754</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>RR</given-names></name><name><surname>Adhikary</surname><given-names>G</given-names></name><name><surname>Simonson</surname><given-names>MS</given-names></name><name><surname>Cherniack</surname><given-names>NS</given-names></name><name><surname>Prabhakar</surname><given-names>NR</given-names></name></person-group><article-title>Role of c-fos in hypoxia-induced AP-1 cis-element activity and tyrosine hydroxylase gene expression</article-title><source>Brain Res Mol Brain Res</source><year>1998</year><volume>59</volume><fpage>74</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">9729288</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glodberg</surname><given-names>MA</given-names></name><name><surname>Schneider</surname><given-names>TJ</given-names></name></person-group><article-title>Similarities between the oxygen sensing mechanisms regulating the expression of vascular endothelin growth factor and erythopoietin</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>4355</fpage><lpage>4359</lpage><pub-id pub-id-type="pmid">8308005</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>MA</given-names></name><name><surname>Gaut</surname><given-names>CC</given-names></name><name><surname>Bunn</surname><given-names>HF</given-names></name></person-group><article-title>Erythropoietin protein mRNA levels are governed by both the rate of gene transcription and post transcriptional events</article-title><source>Blood</source><year>1991</year><volume>77</volume><fpage>271</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">1985693</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prabhakar</surname><given-names>NR</given-names></name><name><surname>Pieramici</surname><given-names>SF</given-names></name><name><surname>Premkumar</surname><given-names>DRD</given-names></name><name><surname>Kumar</surname><given-names>GK</given-names></name><name><surname>Kalaria</surname><given-names>RN</given-names></name></person-group><article-title>Activation of nitric oxide synthase gene expression by hypoxia in central and peripheral neurons</article-title><source>Mol Brain Res</source><year>1996</year><volume>43</volume><fpage>341</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">9037552</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kourembanas</surname><given-names>S</given-names></name><name><surname>Marsden</surname><given-names>PA</given-names></name><name><surname>McQuillan</surname><given-names>LP</given-names></name><name><surname>Faller</surname><given-names>DV</given-names></name></person-group><article-title>Hypoxia induces endothelin gene expression and secretion in cultured human endothelium</article-title><source>J Clin Invest</source><year>1991</year><volume>88</volume><fpage>1054</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">1885767</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Firth</surname><given-names>JD</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name></person-group><article-title>Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>21021</fpage><lpage>21027</lpage><pub-id pub-id-type="pmid">7673128</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Roth</surname><given-names>PH</given-names></name><name><surname>Fang</surname><given-names>HM</given-names></name><name><surname>Wang</surname><given-names>GL</given-names></name></person-group><article-title>Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>23757</fpage><lpage>23763</lpage><pub-id pub-id-type="pmid">8089148</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patiar</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><article-title>Role of hypoxia-inducible factor-1alpha as a cancer therapy target</article-title><source>Endocr Relat Cancer</source><year>2006</year><volume>13</volume><fpage>S61</fpage><lpage>S75</lpage><pub-id pub-id-type="pmid">17259560</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alfranca</surname><given-names>A</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>MD</given-names></name><name><surname>Vara</surname><given-names>A</given-names></name><name><surname>Aragon&#x000e9;s</surname><given-names>J</given-names></name><name><surname>Vidal</surname><given-names>F</given-names></name><name><surname>Land&#x000e1;zuri</surname><given-names>MO</given-names></name></person-group><article-title>Role of c-fos in hypoxia-induced AP-1 cis-element activity and tyrosine hydroxylase gene expression</article-title><source>Mol Cell Biol</source><year>2002</year><volume>22</volume><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11739718</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bi&#x000e8;che</surname><given-names>I</given-names></name><name><surname>Lerebours</surname><given-names>F</given-names></name><name><surname>Tozlu</surname><given-names>S</given-names></name><name><surname>Espie</surname><given-names>M</given-names></name><name><surname>Marty</surname><given-names>M</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name></person-group><article-title>Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>6789</fpage><lpage>6795</lpage><pub-id pub-id-type="pmid">15501955</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bland</surname><given-names>KI</given-names></name><name><surname>Konstadoulakis</surname><given-names>MM</given-names></name><name><surname>Vezeridis</surname><given-names>MP</given-names></name><name><surname>Wanebo</surname><given-names>HJ</given-names></name></person-group><article-title>Oncogene protein co-expression value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma</article-title><source>Ann Surg</source><year>1995</year><volume>221</volume><fpage>706</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">7794075</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langer</surname><given-names>S</given-names></name><name><surname>Singer</surname><given-names>CF</given-names></name><name><surname>Hudelist</surname><given-names>G</given-names></name><name><surname>Dampier</surname><given-names>B</given-names></name><name><surname>Kaserer</surname><given-names>K</given-names></name><name><surname>Vinatzer</surname><given-names>U</given-names></name><name><surname>Pehamberger</surname><given-names>H</given-names></name><name><surname>Zielinski</surname><given-names>C</given-names></name><name><surname>Kubista</surname><given-names>E</given-names></name><name><surname>Schreibner</surname><given-names>M</given-names></name></person-group><article-title>Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters</article-title><source>Eur J Gynaecol Oncol</source><year>2006</year><volume>27</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">17009623</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>DuPre</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Hilsenbeck</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>PH</given-names></name></person-group><article-title>cFos is critical for MCF-7 breast cancer cell growth</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>6516</fpage><lpage>6524</lpage><pub-id pub-id-type="pmid">16027729</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozanne</surname><given-names>BW</given-names></name><name><surname>Spence</surname><given-names>HJ</given-names></name><name><surname>McGarry</surname><given-names>LC</given-names></name><name><surname>Hennigan</surname><given-names>RF</given-names></name></person-group><article-title>Transcription factors control invasion: AP-1 the first among equals</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16799638</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hennigan</surname><given-names>RF</given-names></name><name><surname>Hwaker</surname><given-names>KL</given-names></name><name><surname>Ozanne</surname><given-names>BW</given-names></name></person-group><article-title>Fos-transformation activates genes associated with invasion</article-title><source>Oncogene</source><year>1994</year><volume>9</volume><fpage>3591</fpage><lpage>3600</lpage><pub-id pub-id-type="pmid">7970719</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tkach</surname><given-names>V</given-names></name><name><surname>Tulchinsky</surname><given-names>E</given-names></name><name><surname>Lukanidin</surname><given-names>E</given-names></name><name><surname>Vinson</surname><given-names>C</given-names></name><name><surname>Bock</surname><given-names>E</given-names></name><name><surname>Berezin</surname><given-names>V</given-names></name></person-group><article-title>Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>5045</fpage><lpage>5054</lpage><pub-id pub-id-type="pmid">12902987</pub-id></citation></ref></ref-list></back></article> 